JP7847852B2 - スプライシングを調節するための化合物及び方法 - Google Patents

スプライシングを調節するための化合物及び方法

Info

Publication number
JP7847852B2
JP7847852B2 JP2022552208A JP2022552208A JP7847852B2 JP 7847852 B2 JP7847852 B2 JP 7847852B2 JP 2022552208 A JP2022552208 A JP 2022552208A JP 2022552208 A JP2022552208 A JP 2022552208A JP 7847852 B2 JP7847852 B2 JP 7847852B2
Authority
JP
Japan
Prior art keywords
compound
heteroaryl
aryl
alkyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022552208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515620A (ja
JP2023515620A5 (cg-RX-API-DMAC7.html
Inventor
ドミニク レイノルズ,
マイケル ウォーカー サイラー,
アナント エー. アグラワル,
フレデリック ヴァイランコート,
ピーター スミス,
Original Assignee
リミックス セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リミックス セラピューティクス インコーポレイテッド filed Critical リミックス セラピューティクス インコーポレイテッド
Publication of JP2023515620A publication Critical patent/JP2023515620A/ja
Publication of JP2023515620A5 publication Critical patent/JP2023515620A5/ja
Priority to JP2026060544A priority Critical patent/JP2026108831A/ja
Application granted granted Critical
Publication of JP7847852B2 publication Critical patent/JP7847852B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Replacement Of Web Rolls (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Psychology (AREA)
  • Saccharide Compounds (AREA)
JP2022552208A 2020-02-28 2021-02-28 スプライシングを調節するための化合物及び方法 Active JP7847852B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026060544A JP2026108831A (ja) 2020-02-28 2026-04-01 スプライシングを調節するための化合物及び方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202062983541P 2020-02-28 2020-02-28
US62/983,541 2020-02-28
US202063007333P 2020-04-08 2020-04-08
US63/007,333 2020-04-08
US202063040484P 2020-06-17 2020-06-17
US63/040,484 2020-06-17
US202063072790P 2020-08-31 2020-08-31
US63/072,790 2020-08-31
US202063126492P 2020-12-16 2020-12-16
US63/126,492 2020-12-16
PCT/US2021/020153 WO2021174164A1 (en) 2020-02-28 2021-02-28 Compounds and methods for modulating splicing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026060544A Division JP2026108831A (ja) 2020-02-28 2026-04-01 スプライシングを調節するための化合物及び方法

Publications (3)

Publication Number Publication Date
JP2023515620A JP2023515620A (ja) 2023-04-13
JP2023515620A5 JP2023515620A5 (cg-RX-API-DMAC7.html) 2025-08-22
JP7847852B2 true JP7847852B2 (ja) 2026-04-20

Family

ID=75143749

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2022552208A Active JP7847852B2 (ja) 2020-02-28 2021-02-28 スプライシングを調節するための化合物及び方法
JP2022552209A Active JP7736700B2 (ja) 2020-02-28 2021-02-28 複素環アミド及びスプライシングを調節するためのその使用
JP2025142246A Pending JP2025172876A (ja) 2020-02-28 2025-08-28 複素環アミド及びスプライシングを調節するためのその使用
JP2026060544A Pending JP2026108831A (ja) 2020-02-28 2026-04-01 スプライシングを調節するための化合物及び方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022552209A Active JP7736700B2 (ja) 2020-02-28 2021-02-28 複素環アミド及びスプライシングを調節するためのその使用
JP2025142246A Pending JP2025172876A (ja) 2020-02-28 2025-08-28 複素環アミド及びスプライシングを調節するためのその使用
JP2026060544A Pending JP2026108831A (ja) 2020-02-28 2026-04-01 スプライシングを調節するための化合物及び方法

Country Status (15)

Country Link
US (3) US20240190879A1 (cg-RX-API-DMAC7.html)
EP (3) EP4110464A1 (cg-RX-API-DMAC7.html)
JP (4) JP7847852B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220159386A (cg-RX-API-DMAC7.html)
CN (2) CN115485025A (cg-RX-API-DMAC7.html)
AU (2) AU2021228284A1 (cg-RX-API-DMAC7.html)
BR (2) BR112022017210A2 (cg-RX-API-DMAC7.html)
CA (2) CA3169691A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002342A1 (cg-RX-API-DMAC7.html)
CO (2) CO2022013832A2 (cg-RX-API-DMAC7.html)
CR (2) CR20210483A (cg-RX-API-DMAC7.html)
IL (2) IL295956A (cg-RX-API-DMAC7.html)
MX (2) MX2022010684A (cg-RX-API-DMAC7.html)
SA (1) SA522440338B1 (cg-RX-API-DMAC7.html)
WO (3) WO2021174164A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024532422A (ja) * 2021-08-30 2024-09-05 リミックス セラピューティクス インコーポレイテッド スプライシングを調整するための化合物及び方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
MX2020001425A (es) 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163541A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP7603594B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
IL297963A (en) 2020-05-07 2023-01-01 Adorx Therapeutics Ltd Antagonists of the adenosine a2a receptor
WO2021231571A1 (en) 2020-05-13 2021-11-18 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
IL311135A (en) 2021-08-30 2024-04-01 Remix Therapeutics Inc Compounds and methods for modulating splicing
AU2022394333A1 (en) * 2021-11-17 2024-06-27 Chdi Foundation, Inc. HTT modulators for treating Huntington’s disease
CA3249778A1 (en) * 2022-06-15 2023-12-21 Ptc Therapeutics, Inc. HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF HUNTINGTON'S DISEASE
WO2024086569A1 (en) 2022-10-17 2024-04-25 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
WO2024086570A1 (en) 2022-10-17 2024-04-25 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
TW202440080A (zh) * 2023-03-01 2024-10-16 美商雷密克斯醫療公司 用於調節剪接之化合物及方法
WO2024182788A1 (en) * 2023-03-01 2024-09-06 Remix Therapeutics Inc. Compounds and methods for modulating splicing
TW202535379A (zh) * 2024-01-26 2025-09-16 大陸商成都微芯藥業有限公司 Usp1抑制劑及其製備方法和用途
CN118166099B (zh) * 2024-02-05 2024-10-22 北京大学深圳医院 检测hsa_circ_0014088的试剂在制备诊断口腔鳞状细胞癌的试剂盒中的应用

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007091877A (ja) 2005-09-29 2007-04-12 Fujifilm Corp ナフタロシアニン色素およびその製造方法
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
JP2010500353A (ja) 2006-08-08 2010-01-07 ミレニアム・ファーマシューティカルズ・インコーポレイテッド E1活性化酵素のインヒビターとして有用なヘテロアリール化合物
JP2011513334A (ja) 2008-02-29 2011-04-28 ワイス・エルエルシー ピラゾロ[1,5−a]ピリミジンの架橋二環式複素環式またはスピロ二環式複素環式誘導体、その調製方法および使用
JP2011520941A (ja) 2008-05-23 2011-07-21 ノバルティス アーゲー キノキサリン−およびキノリン−カルボキシアミド誘導体
JP2012528194A (ja) 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション C型肝炎などの疾患を処置するための3つの整列型アリール部分で構成された抗菌性化合物
JP2013529658A (ja) 2010-06-28 2013-07-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌に対する使用のためのキナーゼ阻害剤としての2,4−ジアリール置換[1,8]ナフチリジン
CN104341403A (zh) 2014-10-10 2015-02-11 山东盛华电子新材料有限公司 一种2,5-二杂环取代萘基噁烷衍生物及其制备方法
JP2015516424A (ja) 2012-05-09 2015-06-11 ゾエティス・エルエルシー 駆虫剤としてのアゼチジン誘導体
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
JP2016514134A (ja) 2013-03-11 2016-05-19 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Betブロモドメイン阻害剤およびこれを用いる治療方法
JP2016530231A (ja) 2013-06-25 2016-09-29 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 脊髄性筋萎縮を処置するための化合物
JP2017520570A (ja) 2014-06-25 2017-07-27 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 脊髄性筋萎縮症を処置するためのイミダゾ[1,2−a]ピラジン−1−イルベンズアミド化合物
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
CN109180690A (zh) 2018-10-15 2019-01-11 烟台显华化工科技有限公司 一类用作蓝色荧光材料的氮杂芳香化合物及其应用
WO2019079649A1 (en) 2017-10-18 2019-04-25 Blueprint Medicines Corporation SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
WO2008040951A1 (en) 2006-10-03 2008-04-10 Astrazeneca Ab Compounds
GB0807910D0 (en) * 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
US20110288089A1 (en) 2009-01-22 2011-11-24 Syngenta Crop Protection Llc Insecticidal compounds
CN102020643A (zh) 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
TW201202230A (en) * 2010-05-24 2012-01-16 Mitsubishi Tanabe Pharma Corp Novel quinazoline compound
JP2012028440A (ja) 2010-07-21 2012-02-09 Hitachi Kokusai Electric Inc 基板処理装置及び半導体装置の製造方法
EP3406252B1 (en) 2012-02-10 2020-05-13 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
KR20140125061A (ko) * 2013-04-18 2014-10-28 (주)경인양행 유기발광 화합물 및 이를 포함하는 유기전계발광소자
US9862701B2 (en) 2014-09-25 2018-01-09 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
NL2013636B1 (en) 2014-10-15 2016-10-04 Kraton Polymers Us Llc An accelerator system, a composition comprisng a synthetic isoprene polymer and the accelerator system, and dipped goods made from the composition.
EP3256126B1 (en) 2015-02-09 2024-03-27 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
CN106220644B (zh) * 2015-04-24 2020-07-31 广州再极医药科技有限公司 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
JP2019535789A (ja) 2016-11-28 2019-12-12 ピーティーシー セラピューティクス,インコーポレーテッド Rnaスプライシングを調節する方法
EP3573954A1 (en) * 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP4151627A1 (en) * 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
MX2020001425A (es) 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
US20230152257A1 (en) 2017-09-25 2023-05-18 Skyhawk Therapeutics, Inc. Methods and compositions for screening and identification of splicing
TW201942115A (zh) * 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
JP2021521200A (ja) 2018-04-10 2021-08-26 スカイホーク・セラピューティクス・インコーポレーテッド 癌の処置のための化合物
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020004594A1 (ja) * 2018-06-27 2020-01-02 株式会社リボルナバイオサイエンス 脊髄性筋萎縮症の予防または治療剤
TWI834690B (zh) * 2018-07-18 2024-03-11 美商富曼西公司 用於防治無脊椎動物害蟲之異噁唑啉化合物
US12503467B2 (en) * 2018-12-10 2025-12-23 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors
US20220081412A1 (en) * 2018-12-20 2022-03-17 The Regents Of The University Of Michigan Quinolinyl-pyrazine-carboxamide compounds and uses thereof
KR20220012248A (ko) * 2019-04-22 2022-02-03 베타 파머수티컬 컴퍼니 리미티드 퀴나졸린 화합물 및 이의 의약품에서의 응용
WO2021007378A1 (en) * 2019-07-11 2021-01-14 Ptc Therapeutics, Inc. Compounds for use in treating huntington's disease

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007091877A (ja) 2005-09-29 2007-04-12 Fujifilm Corp ナフタロシアニン色素およびその製造方法
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
JP2010500353A (ja) 2006-08-08 2010-01-07 ミレニアム・ファーマシューティカルズ・インコーポレイテッド E1活性化酵素のインヒビターとして有用なヘテロアリール化合物
JP2011513334A (ja) 2008-02-29 2011-04-28 ワイス・エルエルシー ピラゾロ[1,5−a]ピリミジンの架橋二環式複素環式またはスピロ二環式複素環式誘導体、その調製方法および使用
JP2011520941A (ja) 2008-05-23 2011-07-21 ノバルティス アーゲー キノキサリン−およびキノリン−カルボキシアミド誘導体
JP2012528194A (ja) 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション C型肝炎などの疾患を処置するための3つの整列型アリール部分で構成された抗菌性化合物
JP2013529658A (ja) 2010-06-28 2013-07-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌に対する使用のためのキナーゼ阻害剤としての2,4−ジアリール置換[1,8]ナフチリジン
JP2015516424A (ja) 2012-05-09 2015-06-11 ゾエティス・エルエルシー 駆虫剤としてのアゼチジン誘導体
JP2016514134A (ja) 2013-03-11 2016-05-19 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン Betブロモドメイン阻害剤およびこれを用いる治療方法
JP2016530231A (ja) 2013-06-25 2016-09-29 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 脊髄性筋萎縮を処置するための化合物
JP2017520570A (ja) 2014-06-25 2017-07-27 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 脊髄性筋萎縮症を処置するためのイミダゾ[1,2−a]ピラジン−1−イルベンズアミド化合物
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
CN104341403A (zh) 2014-10-10 2015-02-11 山东盛华电子新材料有限公司 一种2,5-二杂环取代萘基噁烷衍生物及其制备方法
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
WO2019079649A1 (en) 2017-10-18 2019-04-25 Blueprint Medicines Corporation SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE
CN109180690A (zh) 2018-10-15 2019-01-11 烟台显华化工科技有限公司 一类用作蓝色荧光材料的氮杂芳香化合物及其应用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Barsu, Nagaraju et al.,Site-selective C-H bond carbonylation with CO2 and cobalt-catalysis,Catalysis Science & Technology,2018年,8(22),5963-5969.
Havens, Mallory A. et al.,Targeting RNA splicing for disease therapy,Wiley Interdisciplinary Reviews: RNA,2013年,4(3),247-266.
Lu, Xueyi et al.,Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach,Bioorganic & Medicinal Chemistry,2016年,24(18),4424-4433.
Pais, Vania F. et al.,Preparation and pH-Switching of Fluorescent Borylated Arylisoquinolines for Multilevel Molecular Logic,Journal of Organic Chemistry,2013年,78(16),,7949-7961.
REGISTRY(STN)[online],2012.09.18[検索日 2025.01.13] CAS登録番号 1394621-61-4
Srivastava, Sanjay K. et al.,Synthesis and antifilarial profile of 5-amino and 5,8-diamino isoquinoline derivatives: a new class of antifilarial agents,Bioorganic & Medicinal Chemistry Letters,1996年, 6(22),2623-2628.
Suzuki, Takanori et al.,Preparation, properties, and X-ray structures of 5,5'-bi(8-aminoquinoxalyl)s: novel Wurster-type electron donors with a heterobiaryl skeleton,Tetrahedron Letters ,2004年,45(2),329-333.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024532422A (ja) * 2021-08-30 2024-09-05 リミックス セラピューティクス インコーポレイテッド スプライシングを調整するための化合物及び方法

Also Published As

Publication number Publication date
CO2022013827A2 (es) 2022-10-31
WO2021174163A1 (en) 2021-09-02
JP2025172876A (ja) 2025-11-26
CA3169691A1 (en) 2021-09-02
CL2022002342A1 (es) 2023-03-17
CN115485025A (zh) 2022-12-16
WO2021174165A1 (en) 2021-09-02
JP2026108831A (ja) 2026-06-30
CR20220484A (es) 2022-12-15
AU2021228767A1 (en) 2022-09-29
JP7736700B2 (ja) 2025-09-09
JP2023515621A (ja) 2023-04-13
CO2022013832A2 (es) 2022-10-31
EP4110464A1 (en) 2023-01-04
JP2023515620A (ja) 2023-04-13
US20240190879A1 (en) 2024-06-13
MX2022010684A (es) 2023-01-19
CL2022002341A1 (es) 2023-03-10
MX2022010683A (es) 2023-01-19
BR112022017188A2 (pt) 2022-11-08
US20230365566A1 (en) 2023-11-16
CN115515679A (zh) 2022-12-23
CR20210483A (es) 2022-11-25
KR20220158238A (ko) 2022-11-30
EP4110459A1 (en) 2023-01-04
IL295957A (en) 2022-10-01
CA3169709A1 (en) 2021-09-02
EP4110785A1 (en) 2023-01-04
IL295956A (en) 2022-10-01
KR20220159386A (ko) 2022-12-02
BR112022017210A2 (pt) 2022-10-25
AU2021228284A1 (en) 2022-09-29
WO2021174164A1 (en) 2021-09-02
SA522440338B1 (ar) 2025-01-29
US20240226098A1 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
JP7736700B2 (ja) 複素環アミド及びスプライシングを調節するためのその使用
JP7797407B2 (ja) スプライシングを調節するための化合物及び方法
TWI912305B (zh) 調節剪接之化合物及方法
KR20220157407A (ko) 핵산 스플라이싱을 조절하기 위한 피리다진 유도체
AU2021228770A1 (en) Thiophenyl derivatives useful for modulating nucleic acid splicing
IL299543A (en) 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
IL311132A (en) Splicing Modulation Compounds and Methods
KR20260047325A (ko) 스플라이싱을 조절하기 위한 화합물 및 방법

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240227

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250711

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260401

R150 Certificate of patent or registration of utility model

Ref document number: 7847852

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150